Related Experiment Video
Updated: Jul 5, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood
Allison B Reiss1, Shelly Gulkarov1, Aaron Pinkhasov2
1Department of Medicine and Biomedical Research Institute, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA.
Abstract:
Prostate cancer is the second leading cause of cancer death in men in the United States. Androgen deprivation therapy (ADT) is currently the primary treatment for metastatic prostate cancer, and some studies have shown that the use of anti-androgen drugs is related to a reduction in cognitive function, mood changes, diminished quality of life, dementia, and possibly Alzheimer's disease. ADT has potential physiological effects such as a reduction in white matter integrity and a negative impact on hypothalamic functions due to the lowering of testosterone levels or the blockade of downstream androgen receptor signaling by first- and second-generation anti-androgen drugs. A comparative analysis of prostate cancer patients undergoing ADT and Alzheimer patients identified over 30 shared genes, illustrating common ground for the mechanistic underpinning of the symptomatology. The purpose of this review was to investigate the effects of ADT on cognitive function, mood, and quality of life, as well as to analyze the relationship between ADT and Alzheimer's disease. The evaluation of prostate cancer patient cognitive ability via neurocognitive testing is described. Future studies should further explore the connection among cognitive deficits, mood disturbances, and the physiological changes that occur when hormonal balance is altered.
Insights
Androgen deprivation therapy (ADT) for prostate cancer may impact cognitive function and mood. Shared genes between ADT patients and Alzheimer's patients suggest a potential link warranting further investigation.
Area of Science:
- Oncology
- Neurology
- Endocrinology
Background:
- Prostate cancer is a leading cause of cancer death in men.
- Androgen deprivation therapy (ADT) is a primary treatment for metastatic prostate cancer.
- ADT involves anti-androgen drugs that may affect cognitive function, mood, and quality of life.
Purpose of the Study:
- To review the effects of ADT on cognitive function, mood, and quality of life.
- To analyze the relationship between ADT and Alzheimer's disease.
- To explore shared genetic mechanisms between ADT and Alzheimer's disease.
Main Methods:
- Review of existing literature on ADT and its effects.
- Comparative analysis of gene expression in prostate cancer patients on ADT and Alzheimer's patients.
- Description of neurocognitive testing for evaluating cognitive ability in prostate cancer patients.
Main Results:
- ADT may lead to reduced white matter integrity and impact hypothalamic functions.
- Over 30 shared genes were identified between prostate cancer patients on ADT and Alzheimer's patients.
- ADT is associated with potential adverse effects on cognition, mood, and quality of life.
Conclusions:
- ADT may have significant physiological effects impacting cognitive function and mood.
- Shared genetic factors suggest a potential mechanistic link between ADT and Alzheimer's disease.
- Further research is needed to understand the relationship between hormonal changes, cognitive deficits, and mood disturbances.
Related Concept Videos
Menopause
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Psychoneuroimmunology: Diabetes and Cancer
Cognitive Therapy
Alzheimer's Disease: Treatment
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

